Chapter 12: Karen Jenson, Hematologist
The conference center smelled like bad coffee and professional anxiety.
I moved through the registration crowd at 9:15 AM, collecting my credentials under the cover identity I'd established three weeks ago. Independent hematology consultant. Post-CDC research background. The kind of professional profile that invited technical conversation without demanding detailed scrutiny.
Karen Jenson's presentation was scheduled for 10:30.
I'd identified her through Film 1 memory and diagnostic network cross-referencing — her name appeared in three hematology conference registrations this month, and her preliminary research abstract mentioned anomalous retroviral blood samples that my network data suggested came from early blood rave survivors who'd encountered vampire biology before they understood what it was. She was already building the research file that would eventually make her indispensable to Blade's operation.
"Day 10 of synthesis. Thirty hours until integration. After that, my blood work changes permanently."
The timing was deliberate. If I was going to establish professional contact with Karen, I needed to do it before the Tier 2 integration altered my biology in ways that would be harder to mask. My current third-state markers were manageable in brief professional proximity. Post-integration, I'd be more powerful and more detectable. Better to build the baseline relationship now.
The main hall was configured for poster presentations on the lower level and panel sessions on the upper. I found a position near the coffee station — bad coffee, but caffeine was caffeine — and reviewed my approach while the registration crowd filtered into the building.
Karen arrived at 9:47.
I tracked her through the crowd without making direct observation. Blonde hair pulled back in a practical style. Lab coat over professional attire, which suggested she'd come directly from morning hospital rounds. The specific posture of someone who was preparing to present preliminary findings to colleagues who might be skeptical.
Her blood chemistry — what I could read through passive proximity at fifteen meters — was entirely human. No vampire exposure. No retroviral anomalies. Standard cellular architecture.
"Pre-exposure baseline. Useful reference data."
I filed the observation and moved toward the upper level.
Her presentation was more advanced than my Film 1 memory suggested.
Karen had characterized the anomalous blood samples as a novel retroviral modification within three weeks of obtaining them — a timeline that should have taken months of conventional research. She'd identified the specific cellular architecture changes, the coagulation factor abnormalities, and the unusual hemoglobin binding patterns that distinguished vampire-affected blood from standard human samples.
She didn't call it vampire blood. She called it "unknown retroviral pathology with significant clinical implications."
The audience of approximately forty hematologists asked technical questions about her methodology. Karen answered them with the specific confidence of someone who knew her data was solid even if her interpretation was incomplete. She was building toward a conclusion she didn't yet have the framework to articulate: the samples weren't just infected, they were transformed.
I waited until the Q&A concluded before approaching.
"Dr. Jenson." I positioned myself at the edge of her post-presentation cluster, where colleagues were congratulating her on the initial findings. "Your characterization methodology for the retroviral binding patterns — was that adapted from the CDC's arboviral research protocols, or did you develop it independently?"
Karen's attention shifted to me immediately. The question was specific enough that only someone who'd worked with similar biology would know to ask it.
"Independently," she said. "The arboviral protocols assume a single-vector transmission model. These samples show multi-vector characteristics that don't fit standard retroviral architecture."
"The coagulation factor changes support that. Standard retroviral modification affects platelet function primarily. Your samples show red cell membrane alteration that suggests a secondary binding mechanism."
Karen's eyes narrowed slightly — not suspicion, interest. Professional interest from someone who'd just encountered a colleague who understood her work at the level she was working.
"You've seen similar pathology?"
"Post-mortem samples from CDC field investigations. Different context, but the cellular architecture changes match your preliminary characterization."
We talked for twelve minutes.
The conversation required careful navigation. Karen was building toward conclusions that were accurate — the retroviral samples represented a fundamental biological transformation rather than standard infection — and I needed to neither confirm her trajectory nor deflect her from it. I provided one piece of genuinely useful technical input: a characterization methodology from my previous-life CDC experience that would help her isolate the secondary binding mechanism. I asked three questions designed to keep her research moving in the right direction at the right speed.
I did not mention vampires. I did not suggest that her samples came from people who'd been fed on by creatures the medical establishment didn't acknowledge existed. I let her believe she was working on an interesting pathological mystery that would resolve through standard research methodology.
"Managed information asymmetry. The foundation of every relationship I'm building in this timeline."
At the end of the twelve minutes, Karen asked where I was based.
"Independent consultancy. Retroviral pathology focus. Post-CDC." I handed her a business card with contact information that would route through an answering service I'd established for exactly this purpose. "Your research is ahead of schedule. The CDC would be interested if you're open to collaboration."
Karen took the card and wrote my name in her notebook. Before she closed it, I noticed — through the brief physical proximity of the exchange — a separate section labeled in different handwriting: Unknown retroviral patient — non-standard samples.
She wasn't just tracking the conference case. She was building a research file.
"I'll be in touch," she said. "The multi-vector characterization could use a second opinion from someone with field experience."
Her handshake was firm. Her eye contact was direct in the specific way of someone who'd learned that medical colleagues responded better to confidence than uncertainty.
I shook hands and held the contact for approximately two seconds longer than necessary — not for social reasons, but to complete my passive blood chemistry read. Entirely human. No anomalies. Cellular architecture completely standard.
"Pre-exposure baseline: Karen Jenson. Filed."
I categorized the act as clinical and did not investigate whether that categorization was accurate.
The walk back to the lab took forty minutes through midtown foot traffic. I used the time to process the Karen contact and update my operational projections.
Her research timeline was ahead of my Film 1 recall. She'd obtained blood samples and characterized their basic architecture faster than the canonical sequence suggested, which meant either the samples had come from a different source or she'd applied methodology I hadn't anticipated. Either way, the information asymmetry I'd established was fragile — Karen was smart, her research instincts were accurate, and she would eventually figure out that the "unknown retroviral pathology" she was studying was connected to something much larger than a clinical mystery.
"The blood rave is in four days. Curtis Webb — the canonical victim — gets exposed to vampire biology and ends up in Karen's emergency room. After that, her research file stops being theoretical."
I'd built a professional relationship that would survive that transition. When Karen realized her samples came from vampire exposure victims, she'd have a colleague she could contact who understood the pathology. The colleague would be able to provide exactly the right amount of guidance to keep her research productive without exposing the full scope of what she was dealing with.
The colleague was also not human, had third-state biology that was about to undergo a significant transformation, and was managing information asymmetries with everyone he'd ever spoken to in this timeline.
"Standard operational pattern. Nothing unusual."
The lab was quiet when I arrived. The synthesis apparatus showed Day 10, Hour 6 — twenty-eight hours until the integration window opened. Whistler's visit and Blade's follow-up had established a working relationship that would require blood rave data sharing in four days. Karen's conference contact had established a professional baseline that would survive her eventual exposure to vampire biology.
I checked the diagnostic network status. All fourteen nodes operational. Blood rave venue arrays showing continued preparation traffic. Council member tracking stable across the nine marked profiles.
The pieces were aligning. The Tier 2 integration would complete before the blood rave. The blood rave data would give me — and now Blade — comprehensive intelligence on Frost's operation. Karen's research would develop along a trajectory I could guide without revealing my full involvement.
I sat at the analysis terminal and began reviewing the rooftop observation protocols for the blood rave. The venue was surrounded by four buildings with suitable sightlines; I'd need to cycle between two of them to maintain coverage without establishing a detectable pattern.
The synthesis apparatus hummed in the corner. Twenty-eight hours until everything changed.
Karen would start a second notebook page before the conference ended. I knew it would be more accurate than she had any reason to believe.
Get Early Access to New Chapters
Thank you for reading. For those who want to skip the wait, my Patreon offers early access with 7 new chapters every 10 days.
Scout Tier [$5]: +7 Chapters ahead of public sites.
Vanguard Tier [$9]: +14 Chapters ahead of public sites.
World-Eater Tier [$14]: +21 Chapters ahead of public sites.
Support the project and start reading the next arc now: Patreon.com/IsekaiStories